{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"name":"NCT06614192","nct_id":"NCT06614192","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06614192. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive telisotuzumab adizutecan dose A, as part of the approximately 4 year study duration.","label":"Telisotuzumab Adizutecan Dose A","type":"EXPERIMENTAL"},{"description":"Participants will receive telisotuzumab adizutecan dose B, as part of the approximately 4 year study duration.","label":"Telisotuzumab Adizutecan Dose B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-08","type":"ESTIMATED"},"conditions":["Metastatic Colorectal Cancer"],"enrollment":{"count":74,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Telisotuzumab Adizutecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-23","lead_sponsor":"AbbVie","official_title":"AndroMETa-CRC-064: An Open-Label, Randomized Global Dose Optimization Study Comparing Two Doses of Telisotuzumab Adizutecan (ABBV-400) Monotherapy in Subjects With Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants with Adverse Events (AE)s","timeFrame":"Up to a Maximum of 4 Years"},{"measure":"Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator","timeFrame":"Up to a Maximum of 4 Years"},{"measure":"Percentage of Participants with Clinically Significant Electrocardiograms (ECGs) Findings as Assessed by the Investigator","timeFrame":"Up to a Maximum of 4 Years"},{"measure":"Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, Hematology, Coagulation, and Urinalysis) as Assessed by the Investigator","timeFrame":"Up to a Maximum of 4 Years"},{"measure":"Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to a Maximum of 4 Years"},{"measure":"Overall Survival (OS)","timeFrame":"Up to a Maximum of 4 Years"}],"references":[],"start_date":{"date":"2024-11-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT06614192"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06614192"}